SCHEMBL4672230

SCHEMBL4672230

O=C(C=C(O)c1nc[nH]n1)c1cnn(S(=O)(=O)c2ccc(F)cc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.33
MAPT P10636 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MEN1 O00255 2/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
PTGS2 P35354 1/20 0.32
GRM4 Q14833 9/20 0.32
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
RAB9A P51151 1/20 0.31
AKR1C3 P42330 1/20 0.31
POLB P06746 1/20 0.31
HDAC3 O15379 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677715 0.90 GRM4 (0.33) KMT2AMEN1LMNAGRM4ALDH1A1
SCHEMBL4671338 0.84 CXCR3 (0.33) KMT2ALMNAPTGS2ALDH1A1AKR1C3
SCHEMBL4674349 0.82 GRM4 (0.40) KMT2AMEN1PTGS2GRM4ALDH1A1
SCHEMBL4671111 0.80 AKR1C3 (0.38) KMT2AMAPTNPSR1MEN1LMNA
SCHEMBL4671158 0.80 KMT2A (0.32) KMT2AAKR1C3POLBHDAC3HDAC4
SCHEMBL4670937 0.79 MAPT (0.38) KMT2AMAPTNPSR1MEN1LMNA
SCHEMBL4672069 0.78 LMNA (0.43) MAPTLMNAHTTKDM4EALDH1A1
SCHEMBL4673341 0.78 RORC (0.35) KMT2AMAPTLMNAHTTGRM4
SCHEMBL4673557 0.78 KMT2A (0.32) KMT2APOLBHDAC3HDAC4HDAC1
SCHEMBL4675337 0.77 PTGS2 (0.35) KMT2APTGS2GRM4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KMT2A 597/4885MAPT 205/4885NPSR1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.